Shares of Caplin Point Laboratories Ltd. surged 9.4% to hit an intraday high of ₹2,014 apiece around 1.45pm on Thursday, May 14, following the company's strong March quarter performance. According to reports from CNBC TV18, the stock has gained 14% in the past month, reflecting positive investor sentiment toward the pharmaceutical company's financial results. The latest trading data shows continued momentum with the stock maintaining strong performance levels.
The company reported robust fourth quarter results with consolidated net profit increasing 19% to ₹172.88 crore from ₹145.3 crore in the year-ago period. As reported by CNBC TV18, revenue from operations grew 19.4% year-on-year to ₹600 crore from ₹502.5 crore a year ago. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) rose 21.4% to ₹204.2 crore from ₹168 crore in the corresponding quarter last year, with EBITDA margin expanding to 34% from 33.5% a year ago.
For FY26, Caplin Point reported consolidated total income of ₹2,302.73 crore, marking a 13.22% increase from ₹2,033.90 crore in FY25. According to CNBC TV18, consolidated net profit for the year rose to ₹649.73 crore from ₹541.09 crore a year ago. The company's USA business reported revenue of ₹453.4 crore for FY26, while the Rest of the World segment contributed ₹1,733.8 crore. Standalone operations also contributed to growth, with total income rising 5.26% to ₹933.70 crore and net profit at ₹396.58 crore for FY26.
The company's board approved an interim dividend of ₹4 per equity share for FY26, as reported by CNBC TV18. The company has fixed May 30, 2026, as the record date for determining shareholder eligibility for the dividend, providing additional value to investors alongside the strong financial performance. Caplin Point maintains its debt-free status and consolidated equity of ₹3,630.80 crore as of March 31, 2026. However, the company acknowledged a ₹1.39 crore impact on employee benefit obligations due to the assessment of new labour codes, while cash and cash equivalents decreased to ₹94.18 crore from ₹199.45 crore in the prior year due to slower operating cash flow.
The company has committed to an enhanced Capex budget of over ₹1,000 crore for investment projects over the next 2-3 years, with 50% of these projects nearing completion. As reported by CNBC TV18, the focus remains on augmenting production capacities, expanding the product range, and achieving deeper backward integration for its API units. The United States market recorded 28.7% growth in revenue, reaching ₹471 crore, while the company's subsidiary, Caplin Steriles, showed strong momentum in the US, achieving ₹11 million in revenue in its first full year of operations. The company continues to bolster its presence in both emerging and regulated markets, with its Latin American operations remaining a key growth engine.
